Related Experiment Video
Updated: May 5, 2026
10:13
Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding
Published on: June 9, 2017
15.8K
Prolonged receptor blockade by opioid receptor probes
A Koman1, V M Kolb, L Terenius
1Department of Pharmaceutical Pharmacology, Uppsala University, Biomedicum, Box 591, 751 24, Uppsala, Sweden.
Pharmaceutical Research
|November 26, 2013
Summary
Researchers investigated opioid receptor interactions of novel morphinan derivatives. Certain derivatives, like 6-FNX and opioid-steroid hybrids, demonstrated prolonged mu-opioid receptor blockade, independent of chemical reactivity or bivalent structure.
Area of Science:
- Pharmacology
- Neuroscience
- Medicinal Chemistry
Background:
- Opioid receptors are critical targets for pain management and addiction therapies.
- Understanding opioid-receptor interactions is key to developing safer and more effective analgesics.
- Derivatization of morphinan-type opioids offers a route to novel pharmacological probes.
Purpose of the Study:
- To investigate the opioid receptor interactions of morphinan-type opioids modified at the C-6 position.
- To characterize the affinity of these derivatives for the rat brain mu-opioid receptor.
- To screen for and characterize prolonged receptor blockade induced by these novel compounds.
Main Methods:
- Competition binding assays using tritium-labeled dihydromorphine ((3)H-DHM) to determine receptor affinity.
- Preincubation of rat brain membranes with test compounds followed by washing and incubation with (3)H-DHM to assess prolonged blockade.
- Analysis of dissociation profiles of compounds exhibiting prolonged blockade under varying salt concentrations.
Main Results:
- Several C-6 derivatized morphinans, including l-(N-fluoresceinyl naltrexone thiosemicarbazone (6-FNX) and opioid-steroid hybrids (naloxone estrone azine (N-EH), androstene bisoxymorphone azine (O-AD-O)), exhibited persistent mu-opioid receptor blockade.
- This prolonged blockade was observed even under conditions that dissociated parent opioids like naltrexone, naloxone, and oxymorphone.
- Prolonged blockade was achieved by derivatives lacking chemical reactivity or a bivalent opioid structure, distinguishing it from naloxonazine (NAz).
Conclusions:
- Prolonged opioid receptor blockade can be achieved through C-6 derivatization of morphinans, independent of chemical reactivity or bivalent opioid structure.
- Novel derivatives like 6-FNX, N-EH, and O-AD-O serve as valuable tools for studying opioid receptor dynamics.
- These findings open new avenues for designing opioid-based therapeutics with potentially improved duration of action or reduced side effects.
More Related Videos
Related Concept Videos
01:22Opioid Receptors: Overview
7.4K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
7.4K
01:25Analgesia and Pain Management
3.4K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
3.4K
01:20Desensitization and Tachyphylaxis
3.4K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.4K
01:12GPCR Desensitization
6.2K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.2K
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
1.6K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.6K
01:28Drug-Receptor Interaction: Antagonist
4.9K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
4.9K